Destination eradication: we need to boost innovation to end malaria

29 Nov 2019

David Reddy

MMV was founded twenty years ago in the face of an alarming reality – the malaria drug pipeline was dry.

In contrast, today, there are 11 newly launched products that have been brought forward by MMV and partners that have made an immeasurable difference in the fight against the disease.

These medicines are estimated to have saved more than two million lives. And behind those there are many more drugs being developed to address further gaps in the malaria treatment toolbox and showing incredible promise – we now have the richest antimalarial pipeline in history.

Today, we are seeing global cases of malaria on the rise again – the World Health Organization’s (WHO’s) World Malaria Report reveals an eight million increase in cases between 2015 and 2017.

Further, according to WHO, less than 1% of funding for health R&D investment goes to developing tools to tackle malaria – the deadliest disease in history. The reality is that to achieve our shared vision of a malaria-free world, we cannot rely on current tools and methods alone – we need greater innovation to fight back against the continually evolving parasite.

View the full article on The Africa Report website